Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Rodig

Showing results (251-260 of 293) with videos related to

Pageof 30
Sort By:
The New England Journal of Medicine|July 14, 2016
Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S Davids, Haesook T Kim, Pavan Bachireddy, et al.
Blood|November 4, 2022
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S Garcia, Yael Flamand, Livius Penter, et al.
The Journal of Clinical Investigation|March 29, 2022
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapseRoman M Shapiro, Grace C Birch, Guangan Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Journal for Immunotherapy of Cancer|January 8, 2025
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharingJanis M Taube, Joel C Sunshine, Michael Angelo, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
Epstein-Barr Virus Orchestrates Spatial Reorganization and Immunomodulation within the Classic Hodgkin Lymphoma Tumor MicroenvironmentYao Yu Yeo, Huaying Qiu, Yunhao Bai, et al.
Haematologica|April 1, 2021
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMan Chun John Ma, Saber Tadros, Alyssa Bouska, et al.
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2021
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Pageof 30

Showing results (251-260 of 293) with videos related to

Sort By:
Pageof 30
The New England Journal of Medicine|July 14, 2016
Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S Davids, Haesook T Kim, Pavan Bachireddy, et al.
Blood|November 4, 2022
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S Garcia, Yael Flamand, Livius Penter, et al.
The Journal of Clinical Investigation|March 29, 2022
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapseRoman M Shapiro, Grace C Birch, Guangan Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Journal for Immunotherapy of Cancer|January 8, 2025
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharingJanis M Taube, Joel C Sunshine, Michael Angelo, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
Epstein-Barr Virus Orchestrates Spatial Reorganization and Immunomodulation within the Classic Hodgkin Lymphoma Tumor MicroenvironmentYao Yu Yeo, Huaying Qiu, Yunhao Bai, et al.
Haematologica|April 1, 2021
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMan Chun John Ma, Saber Tadros, Alyssa Bouska, et al.
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2021
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Pageof 30